^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    E7 TCR cells

    i
    Other names: E7 TCR cells, E7 TCR T Cell Immunotherapy, E7 TCR T cells
    Associations

    News

    Trials
    Company:
    Gilead, National Cancer Institute
    Drug class:
    Gene transference
    Related drugs:
    Associations

    News

    Trials
    3ms
    E7 TCR T Cells for Human Papillomavirus-Associated Cancers (clinicaltrials.gov)
    P1/2, N=219, Completed, National Cancer Institute (NCI) | Recruiting --> Completed | Trial completion date: Jan 2026 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells
    8ms
    E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers (clinicaltrials.gov)
    P2, N=20, Recruiting, Christian Hinrichs | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells
    3years
    E7 TCR T Cells for Human Papillomavirus-Associated Cancers (clinicaltrials.gov)
    P1/2, N=180, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • Gene therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells
    almost4years
    E7 TCR T Cells for Human Papillomavirus-Associated Cancers (clinicaltrials.gov)
    P1/2, N=180, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jan 2026 --> Dec 2024
    Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells
    4years
    E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=1, Terminated, National Cancer Institute (NCI) | Trial completion date: Apr 2024 --> Dec 2021 | Suspended --> Terminated | Trial primary completion date: Apr 2023 --> Dec 2021; Logistical challenges
    Trial completion date • Trial termination • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    E7 TCR cells
    4years
    E7 TCR T Cell Induction Immunotherapy for Stage IIB-IVA Cervical Cancer (clinicaltrials.gov)
    P1, N=1, Terminated, National Cancer Institute (NCI) | N=180 --> 1 | Trial completion date: Jan 2027 --> Sep 2021 | Suspended --> Terminated | Trial primary completion date: Jan 2022 --> Sep 2021; Multiple logistical challenges
    Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    E7 TCR cells
    over4years
    E7 TCR T Cells for Human Papillomavirus-Associated Cancers (clinicaltrials.gov)
    P1/2, N=180, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jan 2026 --> Dec 2020
    Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells
    almost5years
    E7 TCR T Cells for Human Papillomavirus-Associated Cancers (clinicaltrials.gov)
    P1/2, N=180, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2020 --> Jan 2026
    Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    fludarabine IV • Proleukin (aldesleukin) • E7 TCR cells